

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



PCT/GB 00 / 00 785



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

GB00/785

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

#6

09/914698

REC'D	
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 14 March 2000






T Y



3





The
Patent
Office



05MAR99 E430255-12 D02246
...POL/7700 0.00 - 9905007.2

Request for a grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P006473GB NJN TSG

2. Patent application number
(The Patent Office will fill in this part)

04 MAR 1999

9905007.2

3. Full name, address and postcode of the or of each applicant
(underline all surnames)

David Glover

CRC Cell Cycle Genetics Laboratories
Medical Sciences Institute
University of Dundee
Dundee
DD1 4HN
U.K.

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

U.K.

761472000

4. Title of the invention

Assay

5. Name of your agent (if you have one)

D YOUNG & CO

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

21 NEW FETTER LANE
LONDON
EC4A 1DA

Patents ADP number (if you have one)

59006

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country

Priority application
number
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form None

Description 37

Claims(s) 3

Abstract 1

Drawing(s) 4

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)


Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date



D YOUNG & CO
Agents for the Applicants

4 March 1999

12. Name and daytime telephone number of the person to contact in the United Kingdom

Neil Nachshen

0171 353 43

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- b) Write your answers in capital letters using black ink or you may type them
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Field of the Invention

The present invention relates to the use of the Asp protein or homologues thereof in a method of identifying substances capable of arresting cells in mitosis by disrupting microtubule organising centre formation and/or maintenance. Such substances may be used in therapeutic methods to inhibit cell growth.

Background to the Invention

The aim of many anti-cancer therapies is to inhibit cell division, i.e. mitosis, in tumour cells. Assembly of the spindle apparatus is a key event in cell mitosis since the spindle apparatus is required for chromosome segregation between daughter cells. Spindle apparatus assembly is thus a potential target for inhibition of mitosis and tumour therapy.

The spindle apparatus comprises microtubules which are organised at its poles by a microtubule organising centre (MTOC) that in most animal cells is termed the centrosome. The centrosome itself usually comprises a pair of centrioles associated with a cloud of poorly defined pericentriolar material (PCM). During interphase, the PCM nucleates a cytoplasmic array of microtubules that project outward toward the cell perimeter. Duplication of the centrosome occurs during interphase. The two centrosomes remain together as a single complex prior to mitosis but as mitosis begins, this complex splits in two. Each centrosome then serves as a separate MTOC that nucleates a radial array of microtubules called an aster. The two asters move to opposite sides of the nucleus to form the two poles of the mitotic spindle.

Several mutations have been identified in a variety of experimental organisms that result in defects in spindle formation. Once such mutation, the *asp* mutation, was originally identified in *Drosophila* by Ripoll *et al.*, 1975. The *asp* gene has been cloned in *Drosophila* and shown to encode a highly basic protein with a molecular weight of 220 kDa comprising putative actin and calmodulin binding domains (Saunders *et al.*, 1997).

The abnormal spindle microtubules seen in meiosis and in mitosis of a variety of cell types led Saunders *et al.*, 1997 to speculate that the *asp* gene product was involved in some aspect of spindle microtubule dynamics. The association of Asp with microtubules was demonstrated by the finding that it copurified with taxol stabilised microtubules and remained associated following a wash with 0.4 M NaCl. Immunolocalisation of the Asp protein within syncytial embryos was consistent with this finding. The Asp protein was present in the cytoplasm during interphase, and on microtubules in the polar regions of the spindle in mitosis until telophase, when it became associated with the central region of the spindle (Saunders *et al.*, 1997).

Summary of the Invention

We have now shown that, contrary to previous findings indicating that Asp is a microtubule associated protein localised to the centrosomes of mitotic spindles, Asp is in fact associated with the centrosome throughout mitosis and is present on the centrosome following its isolation *in vitro*. Furthermore, we have shown that depletion of Asp from *Drosophila* embryo extracts results in the loss of the ability of the extracts to restore microtubule organising centre (MTOC) activity to salt-stripped centrosome preparations. We have also shown that antibodies directed against the Asp protein block microtubule nucleation from the centrosomes in a dose-dependent manner.

Thus substances that bind to Asp and interfere with the interaction of Asp with the centrosome may be used to disrupt MTOC integrity and consequently normal spindle formation, resulting in mitotic arrest. These substances may therefore also be used to inhibit mitosis and cellular proliferation.

Accordingly the present invention provides a method for identifying a substance capable of disrupting microtubule organising centre (MTOC) integrity, which method comprises contacting an Asp polypeptide or homologue thereof, or fragment thereof capable of forming and/or maintaining MTOCs in the absence of the substance, with a candidate substance in the presence of components required for MTOC formation and microtubule

nucleation therefrom, and determining whether the substance disrupts MTOC integrity.

The term "disrupting MTOC integrity" means reducing or preventing the formation and/or maintenance of MTOCs, particularly centrosomes, capable of nucleating microtubules assembly from an organised centre to produce aster-like polymerised microtubule structures, such as asters themselves.

In one preferred embodiment, said components comprise KI-extracted centrosomes and an Asp-depleted soluble cellular extract. In another preferred embodiment, said components comprise a partially purified centrosome preparation and tubulin.

Preferably said Asp polypeptide is as shown in SEQ I.D. No. 1 or a fragment or derivative thereof capable of stimulating the formation of and/or maintaining MTOCs. Alternatively, said Asp polypeptide is a mammalian homologue of the polypeptide shown in SEQ I.D. No. 1, or a fragment or derivative thereof capable of stimulating the formation of and/or maintaining MTOCs. In particular, it is preferred to use a human homologue or fragment thereof.

Candidate substances identified by the assay method of the invention may be further tested in mitosis inhibition assays comprising administering substance, which has been determined to disrupt MTOC integrity by the assay method described above, to a cell and determining whether the substance inhibits mitosis in the cell.

The present invention further provides a substance identified by the method of the invention.

The present invention also provides a substance capable of disrupting MTOC integrity which substance is selected from peptides consisting essentially of from 5 to 35 amino acids comprising a amino acid sequence selected from residues x-y of SEQ I.D. No. 1 wherein x-y is 267-271, 272-276, 291-295, 387-391, 421-425, 473-477, 140-144, 237-241, 269-273, 471-475, 155-160, 237-243, 743-875, 911-940, 1293-1322, 1374-1403, 1563-1591 and 1597-1624.

The present invention further provides a substance capable of binding to an Asp polypeptide or homologue or fragment thereof for use in a method of disrupting MTOC integrity. An example of a suitable substance is an anti-Asp antibody.

The present invention also provides a polypeptide fragment of an Asp polypeptide or homologue thereof, which fragment is not capable of restoring microtubule nucleation centre organising activity to an Asp-depleted extract, for use in a method of disrupting MTOC integrity.

Preferably said polypeptide fragment of an Asp polypeptide, which fragment is not capable of restoring microtubule nucleation centre organising activity to an Asp-depleted extract, is selected from peptides consisting essentially of from 5 to 35 amino acids comprising a amino acid sequence selected from residues x-y of SEQ I.D. No. 1 wherein x-y is 267-271, 272-276, 291-295, 387-391, 421-425, 473-477, 140-144, 237-241, 269-273, 471-475, 155-160, 237-243, 743-875, 911-940, 1293-1322, 1374-1403, 1563-1591 and 1597-1624.

The present invention further provides a polynucleotide encoding a polypeptide fragment, which fragment is not capable of restoring microtubule nucleation centre organising activity to an Asp-depleted extract, for use in a method of disrupting MTOC integrity. A nucleic acid vector comprising said polynucleotide is also provided.

The present invention also provides the use of an Asp polypeptide or homologue thereof, or fragment thereof capable of stimulating formation of and/or maintaining MTOCs, in an assay for identifying a substance capable of disrupting MTOC integrity.

In a further embodiment the invention provides a substance capable of disrupting MTOC integrity, for example a substance identified by the method of the invention, for use in a method of disrupting MTOC integrity.

In another embodiment the present invention provides a process comprising the steps of:

- (a) performing the method of the invention; and

- (b) preparing a quantity of those one or more substances identified as being capable of disrupting MTOC integrity.

The present invention also provides a process comprising the steps of:

- (a) performing the method of the invention; and
- (b) preparing a pharmaceutical composition comprising one or more substances identified as being capable of disrupting MTOC integrity.

Detailed Description of the Invention

Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (1989); Ausubel *et al.*, Current Protocols in Molecular Biology (1995) and John Wiley & Sons, Inc.

A. Asp polypeptides

Asp polypeptides for use in the assay methods of the present invention include the *Drosophila* Asp polypeptide, described in Saunders *et al.*, 1997, and homologues, variants, derivatives and fragments thereof. The amino acid and nucleotide sequence of *Drosophila* Asp described in Saunders *et al.*, 1997 is shown as SEQ I.D. No 1.

Accordingly, it will be understood that the Asp amino acid sequences for use in the present invention are not limited to the sequence set out in SEQ I.D. 1 or sequences obtained therefrom but also include homologous sequences obtained from any source, for example allelic variants, related cellular homologues, species homologues and synthetic peptides, as well as variants or derivatives thereof.

Thus, the present invention covers variants, homologues or derivatives of the amino acid sequences of the present invention, as well as variants, homologues or derivatives of the nucleotide sequence coding for the amino acid sequences of the present invention. With respect to fragments, truncated versions of the above may be used in the assays of the

present invention provided that the fragments are capable of stimulating MTOC formation and/or maintenance as determined by the ability of the MTOCs to nucleate asters.

The term "microtubule nucleation centre" means a centrosome that is capable of acting as a centre for microtubule nucleation. Preferably, the centrosome is capable of acting as a centre for microtubule nucleation during mitosis. Thus the term "microtubule nucleation centre" refers to an intact MTOC (centrosome) that is capable of nucleating asters of microtubules.

The term "microtubule organising centre integrity" used throughout includes both the formation of MTOCs and their maintenance in a state capable of nucleating asters.

In the context of the present invention, a homologous sequence is taken to include an amino acid sequence which is at least 20, 30, 40 or 50% identical at the amino acid level over at least 10, 20, 50 or 100, preferably at least 200, 500 or 1000 amino acids with SEQ I.D. No. 1. In particular, homology should typically be considered with respect to those regions of the sequence known to be essential for microtubule organising centre integrity rather than non-essential neighbouring sequences. For example it is preferred that a higher degree of homology occurs in the regions of the polypeptide containing, for example, one or more p34^{cdc2} consensus phosphorylation sites (such as residues 267-271, 272-276, 291-295, 387-391, 421-425 or 473-477 of SEQ I.D. No. 1), one or more MAP kinase consensus phosphorylation sites (such as residues 140-144, 237-241, 269-273 or 471-475 of SEQ I.D. No. 1), one or more monoclonal antibody MPM2 epitope phosphorylation sites (such as residues 155-160, or 237-243 of SEQ I.D. No. 1), a putative actin binding site (such as residues 743-875 of SEQ I.D. No. 1) or one or more IQ motifs (sites of interaction with members of the calmodulin family of proteins (Cheney and Mooseker, 1992)) (such as residues 911-940, 1293-1322, 1374-1403, 1563-1591 or 1597-1624 of SEQ I.D. No. 1).

Homologous sequences can typically be obtained from other sources, such as mammalian, in particular human cells, by cloning procedures such as those described below.

Particularly preferred homologues comprise one or more of the following features, preferably all of the following features.

- (i) a molecular weight of from 150 to 300 kDa, preferably about 220 kDa, as determined by SDS-PAGE
- (ii) basic charge at physiological pH;
- (iii) an N-terminal domain comprising one or more p34^{cdc2} consensus phosphorylation site, one or more MAP kinase consensus phosphorylation site; and/or one or more MPM2 epitope phosphorylation sites;
- (iv) a central domain comprising a putative actin binding site; and
- (v) a C-terminal coiled-coiled domain containing two or more IQ motifs.

A particular feature of the *Drosophila* Asp protein is the presence of an extensive C-terminal coiled-coil domain containing multiple I.Q. motifs (item (v) above). The primary amino acid sequence of coiled-coil domains may diverge markedly during evolution. Consequently for the purposes of the present invention, homology in this region may be predicted using the coiled-coil prediction program "COILS" (Lupas *et al.*, 1991).

Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids).

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux *et al.*, 1984, Nucleic Acids Research 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see <http://www.ncbi.nih.gov/BLAST/>), FASTA (Atschul *et al.*, 1990, J. Mol. Biol., 403-410; FASTA is available for online searching at, for example, <http://www.2.ebi.ac.uk.fasta3>) and the GENWORKS suite of comparison tools. However it is preferred to use the GCG Bestfit program.

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

The terms "variant" or "derivative" in relation to the amino acid sequences of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence has activity in organising a microtubule nucleation centre, preferably having at least the same activity as the amino acid sequence shown as SEQ I.D. No. 1.

Any Asp sequence for use in the present invention may be modified. Typically, modifications are made that maintain the ability of the sequence to maintain microtubule organising centre integrity. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains activity in maintaining microtubule organising centre integrity, preferably at least 50% of the activity of the Asp polypeptide shown as SEQ I.D. No. 1, more preferably at least the same activity. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the

third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Asp polypeptides for use in the invention may be made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides for use in the invention may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the protein of interest in maintaining microtubule organising centre integrity.

Alternatively, Asp polypeptides may be purified from vertebrate cells, such as insect or mammalian cells. A detailed protocol is described in section E.

Proteins for use in the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A protein of the invention may also be in a substantially purified form, in which case it will

generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is an Asp polypeptide.

B. Polynucleotides

Polynucleotides for use according to the invention comprise nucleic acid sequences encoding the amino acid sequences of the invention. They also include the *Drosophila* Asp cDNA sequence shown as SEQ I.D. No. 2, homologues, derivatives, variants and fragments. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides for use according to the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed.

Polynucleotides for use according to the present invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides of the invention.

The terms "variant", "homologue" or "derivative" in relation to the nucleotide shown as SEQ I.D. No.2 include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for a polypeptide having activity in organising microtubule nucleation centres, preferably having at least 50% of the activity as the sequence presented in SEQ I.D. No.1, more preferably at least the same activity.

As indicated above, with respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listing herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described above. A preferred sequence comparison program is the GCG Winsconsin Bestfit program described above. The default scoring matrix has a match value of 10 for each identical nucleotide and -9 for each mismatch. The default gap creation penalty is -50 and the default gap extension penalty is -3 for each nucleotide.

The present invention also encompasses nucleotide sequences for use according to the present invention that are capable of hybridising selectively to the sequences presented herein, or any variant, fragment or derivative thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length.

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction technologies.

Polynucleotides for use according to the invention capable of selectively hybridising to the nucleotide sequences presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequence of SEQ I.D. No. 2 over a region of at least 20, preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous nucleotides. Preferred polynucleotides for use according to the invention will comprise regions homologous to nucleotides encoding the particular regions described above for polypeptides, preferably at least 80 or 90% and more preferably at least 95% homologous.

The term "selectively hybridizable" means that the polynucleotide used as a probe is used under conditions where a target polynucleotide of the invention is found to hybridize to the probe at a level significantly above background. The background hybridization may occur

because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P .

Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to a nucleotide sequence for use according to the present invention under stringent conditions (e.g. 65°C and $0.1\times\text{SSC}$ { $1\times\text{SSC} = 0.15\text{ M NaCl}$, $0.015\text{ M Na}_3\text{ Citrate pH } 7.0$ }).

Where the polynucleotide for use according to invention is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present invention. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included within the scope of the present invention.

Polynucleotides which are not 100% homologous to the sequences for use according to the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by

probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other cellular homologues may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of SEQ I.D. No 2 under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences set out in the sequence listing.

Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.

The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Polynucleotides encoding homologues of *Drosophila* Asp from other species, in particular mammals such as humans, may be obtained by purifying the homologous protein present in cells from such species, deducing the amino acid sequence and using the sequence to design degenerate probes/PCR primers as described above. Section E outlines a procedure for purifying Asp protein or homologues thereof from cell extracts. The complete or partial sequence of such a purified protein may be obtained by methods well-known in the art such as mass-spectroscopy and/or chemical sequencing (e.g. enzymatic digestion and Edmann degradation). The complete or partial nucleotide sequence of the Asp homologue can then be predicted from knowledge of the genetic code. If only partial sequence information is available, the remainder of the sequence may be obtained using standard cloning techniques.

Alternatively, Asp polynucleotides may be obtained by site directed mutagenesis of characterised sequences, such as SEQ ID. No 2. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

Polynucleotides for use according to the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides for use in the invention as used herein.

Polynucleotides such as a DNA polynucleotides and probes for use according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the Asp sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector

C. Nucleotide vectors

Polynucleotides for use in the present invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides for use in the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

Preferably, a polynucleotide for use according to the invention in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.

Vectors for use according to the invention may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein.

The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable

marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.

Control sequences operably linked to sequences encoding Asp polypeptides include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in. The term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.

The promoter is typically selected from promoters which are functional in mammalian cells, although prokaryotic promoters and promoters functional in other eukaryotic cells, in particular insect cells, may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. With respect to eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α -actin, β -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

D. Host cells

Vectors and polynucleotides for use according to the invention may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing Asp polypeptides. Although the Asp polypeptides may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in particular mammalian cells.

Vectors/polynucleotides for use in the invention may introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art, for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation.

E. Protein Expression and Purification

Host cells comprising polynucleotides for use according to the invention may be used to express proteins for use according to the invention. Host cells may be cultured under suitable conditions which allow expression of the Asp polypeptides. Expression of the Asp polypeptides may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by, for example, addition of an inducer substance to the culture medium, for example dexamethasone or IPTG.

Proteins for use according to the invention can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption.

Polypeptides for use in the present invention may also be purified from extracts of cells in which they naturally occur. For example, *Drosophila* Asp may be purified from *Drosophila* embryos. Source cells may be, for example, obtained from whole organisms

or from cells in tissue culture. A particular purification protocol for *Drosophila* Asp from embryos is as follows.

Drosophila embryos are collected over a three hour period and dechorionated by incubation in 50% sodium hypochloride for 3 min. The bleach is then removed by extensive washes with water. Embryos are then washed in lysis buffer (0.1 M Pipes/NaOH, pH 6.6, 5 mM EGTA, 1 mM MgSO₄, 0.9 M glycerol, 1 mM DTT, 1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin and 1 mg/ml pepstatin). About 3 ml of embryos are homogenised in 2 volumes of ice-cold lysis buffer with a Dounce homogeniser or a pestle and mortar. The microtubules are depolymerised by incubation on ice for 15 min and the extract centrifuged at 16,000 g for 30 min at 4°C. The supernatant is recentrifuged at 135,000 g for 90 min at 4°C. Microtubules in the resulting supernatant are polymerised by addition of GTP to a final concentration of 1 mM, addition of taxol to a final concentration of 20 µM and incubation at room temperature for 30 min. 3 ml aliquots of extract are layered on top of 3 ml 15% sucrose cushions prepared in lysis buffer supplemented with 20 µM taxol and 1 mM GTP. After centrifuging at 54,000 g for 30 min at 20°C using a swing out rotor, the pellet is suspended in lysis buffer containing taxol and GTP. This also provides a suitable cell extract for use in microtubule nucleation assays described below.

To extract the microtubule associated proteins, the pellet is extracted with 400-500 mM NaCl. After centrifugation, the pellet is then extracted with 1 M NaCl, centrifuged and finally extracted with 1-2 M KI. Purified Asp protein is present in the soluble KI fraction which is then typically concentrated ultrafiltration using Millipore Ultrafree systems. Fractions may also be dialysed against a suitable buffer prior to storage and use.

We have shown that using this purification technique, the protein retains biological activity and when added to an asp-mutant embryo extract it can correct the defect in organisation of the microtubule nucleating activity of centrosomes. Modified protocols will be applicable to other types of organisms. For example, protocols are known to the skilled person for the purification of mammalian microtubules and their associated proteins (MAPs). Once the MAPs have been extracted according to these protocols using NaCl, the Asp protein may typically still be present in the pellet. The Asp protein may then be extracted with

1-2 M KI. Exact conditions may vary but may easily be determined by a person skilled in fractionation of cellular extracts.

F. Assays

The assays of the present invention are suitable for identifying substances that inhibit microtubule nucleation centre organising activity mediated by an Asp polypeptide (reference to which includes homologues, variants, derivatives and fragments as described above). Such assays are typically *in vitro*. Assays are also provided that test the effects of candidate substances identified in preliminary *in vitro* assays on intact cells in whole cell assays.

Candidate substances

A substance that inhibits microtubule nucleation centre organising activity (i.e. maintenance of MTOC integrity) mediated by an Asp polypeptide may do so in several ways. It may directly disrupt the binding Asp to a component of the centrosome of the two components by, for example, binding to Asp and masking or altering the site of interaction with the other component. Candidate substances of this type may conveniently be preliminarily screened by *in vitro* binding assays as, for example, described below and then tested in a microtubule nucleation assay as described below. Examples of candidate substances include antibodies which recognise Asp.

A substance which can bind directly to Asp may also inhibit its microtubule nucleation centre organising activity by altering its subcellular localisation thus preventing Asp and components of the centrosome from coming into contact within the cell. This can be tested using, for example the whole cells assays described below. Non-functional homologues of Asp may also be tested for inhibition of microtubule nucleation centre organising activity since they may compete with Asp for binding to components of the centrosome whilst being incapable of stimulating microtubule organising centre nucleation activity or block the function of Asp bound to the centrosome. Such non-functional homologues may include naturally occurring Asp mutants and modified Asp sequences or fragments thereof.

Alternatively, instead of preventing the association of the components directly, the substance may suppress the biologically available amount of Asp. This may be by inhibiting expression of the component, for example at the level of transcription, transcript stability, translation or post-translational stability. An example of such a substance would be antisense RNA or double-stranded interfering RNA sequences which suppresses the amount of Asp mRNA biosynthesis.

Suitable candidate substances include peptides, especially of from about 5 to 30 or 10 to 25 amino acids in size, based on the sequence of the various domains of *Drosophila Asp* described in section A, or variants of such peptides in which one or more residues have been substituted. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.

Particularly preferred peptides include peptides containing, for example, one or more p34^{cdc2} consensus phosphorylation sites (such as residues 267-271, 272-276, 291-295, 387-391, 421-425 or 473-477 of SEQ I.D. No. 1), one or more MAP kinase consensus phosphorylation sites (such as residues 140-144, 237-241, 269-273 or 471-475 of SEQ I.D. No. 1), one or more monoclonal antibody MPM2 epitope phosphorylation sites (such as residues 155-160, or 237-243 of SEQ I.D. No. 1), a putative actin binding site (such as residues 743-875 of SEQ I.D. No. 1) or one or more IQ motifs (sites of interaction with members of the calmodulin family of proteins (Chen and Mooseker, 1992)) (such as residues 911-940, 1293-1322, 1374-1403, 1563-1591 or 1597-1624 of SEQ I.D. No. 1). These peptides may be modified by insertion, deletion or substitution (including the use of non-naturally occurring amino acids and analogues).

Thus preferred peptides include peptides consisting essentially of from 5 to 35 amino acids comprising a amino acid sequence selected from residues x-y of SEQ I.D. No. 1 wherein x-y is 267-271, 272-276, 291-295, 387-391, 421-425, 473-477, 140-144, 237-241, 269-273, 471-475, 155-160, 237-243, 743-875, 911-940, 1293-1322, 1374-1403, 1563-1591 and 1597-1624.

Suitable candidate substances also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for Asp. Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as inhibitors of Asp-mediated microtubule nucleation centre organising activity in assays such as those described below. The candidate substances may be used in an initial screen in batches of, for example 10 substances per reaction, and the substances of those batches which show inhibition tested individually. Candidate substances which show activity in *in vitro* screens such as those described below can then be tested in whole cell systems, such as mammalian cells which will be exposed to the inhibitor and tested for inhibition of mitosis.

Asp binding assays

One type of preliminary assay for identifying substances that bind to Asp involves contacting an Asp polypeptide, which is immobilised on a solid support, with a non-immobilised candidate substance determining whether and/or to what extent the Asp polypeptide and candidate substance bind to each other. Alternatively, the candidate substance may be immobilised and the Asp polypeptide non-immobilised.

In a preferred assay method, the Asp polypeptide is immobilised on beads such as agarose beads. Typically this is achieved by expressing the component as a GST-fusion protein in bacteria, yeast or higher eukaryotic cell lines and purifying the GST-fusion protein from crude cell extracts using glutathione-agarose beads (Smith and Johnson, 1988). As a control, binding of the candidate substance, which is not a GST-fusion protein, to the immobilised Asp polypeptide is determined in the absence of the Asp polypeptide. The binding of the candidate substance to the immobilised Asp polypeptide is then determined. This type of assay is known in the art as a GST pulldown assay. Again, the candidate substance may be immobilised and the Asp polypeptide non-immobilised.

It is also possible to perform this type of assay using different affinity purification systems for immobilising one of the components, for example Ni-NTA agarose and histidine-tagged components.

Binding of the Asp polypeptide to the candidate substance may be determined by a variety of methods well-known in the art. For example, the non-immobilised component may be labelled (with for example, a radioactive label, an epitope tag or an enzyme-antibody conjugate). Alternatively, binding may be determined by immunological detection techniques. For example, the reaction mixture can be Western blotted and the blot probed with an antibody that detects the non-immobilised component. ELISA techniques may also be used.

Microtubule organising centre nucleation activity assays

Candidate substances, for example those identified using the Asp binding assays described above, may be screening using a microtubule organising centre nucleation activity assay to determine if they are capable of disrupting MTOCs as measured by, for example, aster formation. This assay in its simplest form comprises adding the candidate substance to a cellular extract which in the absence of the candidate substance has microtubule organising centre nucleation activity resulting in formation of asters.

In a preferred embodiment, the assay system comprises (i) an Asp polypeptide or homologue, variant, derivative, fragment thereof and (ii) components required for microtubule organising centre nucleation activity except for functional Asp, which is typically removed by immunodepletion (or by the use of extracts from Asp mutants). The components themselves are typically in two parts such that microtubule nucleation does not occur until the two parts are mixed (microtubule nucleation can take place in the absence of Asp but the result is a mass of disorganised microtubules rather than normal aster - see Figure 4A vs Figure 4C). The Asp may be present in one of the two parts initially or added subsequently prior to mixing of the two parts.

Subsequently, the Asp polypeptide and candidate substance are added to the component mix and microtubule nucleation from centrosomes measured, for example by immunostaining for Asp and visualising aster formation by immuno-fluorescence microscopy. Asp polypeptide may be preincubated with the candidate substance before addition to the component mix. Alternatively, both Asp polypeptide and the candidate substance may be added directly to the component mix, simultaneously or sequentially in either order.

The components required for microtubule organising centre formation typically include salt-stripped centrosomes prepared as described in Moritz *et al.*, 1998. Stripping centrosome preparations with 2 M KI removes the centrosome proteins CP60, CP190, CNN and γ -tubulin. Of these, neither CP60 nor CP190 appear to be required for microtubule nucleation. The other minimal components are typically provided as an Asp-depleted cellular extract, or conveniently, as a cellular extract from cells with non-functional Asp, for example *Drosophila* embryo extracts from asp-mutant embryos. Typically, labelled tubulin (usually β -tubulin) is also added to assist in visualising aster formation.

Alternatively, partially purified centrosomes that have not been salt-stripped may be used as part of the components. In this case, only tubulin, preferably labelled tubulin is required to complete the component mix.

Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 μ g/ml, more preferably from 200 to 300 μ g/ml.

The degree of inhibition of aster formation by the candidate substance may be determined by measuring the number of normal asters per unit area for control untreated cell preparation and measuring the number of normal asters per unit area for cells treated with the candidate substance and comparing the result. Typically, a candidate substance is considered to be capable of disrupting MTOC integrity if the treated cell preparations have

less than 50%, preferably less than 40, 30, 20 or 10% of the number of asters found in untreated cells preparations. It may also be desirable to stain cells for γ -tubulin to determine the maximum number of possible MTOCs present to allow normalisation between samples.

Whole cell assays

Candidate substances may also be tested on whole cells for their affect microtubule organising centre integrity and downstream affects on mitosis. Preferably the candidate substances have been identified by the above-described *in vitro* methods. Alternatively, rapid throughout screens for substances capable of inhibiting mitosis may be used as a preliminary screen and then used in the *in vitro* assay described above to confirm that the affect is on MTOC integrity.

The candidate substance, i.e. the test compound, may be administered to the cell in several ways. For example, it may be added directly to the cell culture medium or injected into the cell. Alternatively, in the case of polypeptide candidate substances, the cell may be transfected with a nucleic acid construct which directs expression of the polypeptide in the cell. Preferably, the expression of the polypeptide is under the control of a regulatable promoter.

Typically, an assay to determine the effect of a candidate substance identified by the method of the invention on cell mitosis comprises administering the candidate substance to a cell and determining whether the substance inhibits mitosis. Techniques for measuring mitosis in a cell population are well known in the art. The extent of mitosis in treated cells is compared with the extent of mitosis in an untreated control cell population to determine the degree of inhibition, if any. Cells may also be examined by fluorescence microscopy using suitable antibodies to microtubule/aster components to determine any effects on microtubule nucleation in treated cells.

The concentration of candidate substances used will typically be such that the final concentration in the cells is similar to that described above for the *in vitro* assays.

A candidate substance is typically considered to be an inhibitor of mitosis if mitosis is reduced to below 50%, preferably below 40, 30, 20 or 10% of that observed in untreated control cell populations.

G. Therapeutic Uses

Since inhibition of microtubule nucleation will generally inhibit cellular mitosis, substances capable of inhibiting Asp-mediated maintenance or MTOCs, typically identified by the methods of the invention, may be used to inhibit mitosis, for example in rapidly dividing cells such as are found in tumour tissue. Thus substances capable of inhibiting Asp-mediated maintenance or MTOCs may be used in a method of inhibiting mitosis in a cell such as a mammalian cell, preferably a human cell. In a preferred embodiment, the cell is a tumour cell.

H. Administration

Substances identified or identifiable by the assay methods of the invention may preferably be combined with various components to produce compositions of the invention. Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition of the invention may be administered by direct injection. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

Polynucleotides/vectors encoding polypeptide components for use in inhibiting mitosis may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome. When the polynucleotides/vectors are administered as a naked nucleic acid, the amount of nucleic

acid administered may typically be in the range of from 1 μ g to 10 mg, preferably from 100 μ g to 1 mg. . It is particularly preferred to use polynucleotides/vectors that target specifically tumour cells, for example by virtue of suitable regulatory constructs or by the use of targeted viral vectors.

Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.

Preferably the polynucleotide or vector according to the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.

The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention. The Examples refer to the Figures. In the Figures:

Figure 1 Antibodies to Asp decorate the centrosome, and can block microtubule nucleating activity *in vitro*. [A through C] show the immunolocalisation of Asp in wild-type neuroblasts from *Drosophila* third instar larvae. A: Immunolocalisation of γ -tubulin (green), Asp (red), and DNA (blue) at metaphase. B: The same cell is shown as in A but only with Asp staining. C: An early anaphase cell showing α -tubulin(green), Asp (red),

and DNA (blue). [D through F] show preparations of centrosomes from *Drosophila* embryos. D: γ -tubulin (blue). E: Asp (green). F: A merge of the two previous images also showing the asters of microtubules obtained after incubation with rhodamine-labelled tubulin. Panel G is a Immunoblot of the fractions from the final sucrose gradient centrifugation in the centrosome purification procedure. The 70% sucrose cushion was discarded, and the indicated fractions are the first six of a total of 26 in the remaining gradient. Asp and γ -tubulin co-sediment in fractions 4 and 5 as indicated. Fraction 5 was used in the experiments here. Panel H shows antibody competition assays in which centrosomes were first incubated with 0-0.3 μ g/ml affinity purified anti-Asp, before being used in microtubule nucleation assays and finally being immunostained to reveal γ -tubulin. Preparations were scored for the total number of asters of microtubules and total centrosomes as indicated by foci of γ -tubulin. Scale bars, 10 μ m.

Figure 2 Mitosis in *asp* mutants have unfocused spindle poles with disorganised γ -tubulin. Panels A and B show metaphase arrested cells in *asp^{dd4}* mutant brains in which α -tubulin is stained green and DNA is stained blue. A wild-type spindle is shown in the inset of panel A. Panels C and D show γ -tubulin (red) and DNA (blue) in *asp^{dd4}* brains (compare with the wild-type cell in Figure 1A). Scale bars, 10 μ m.

Figure 3 Restoration of MTOC activity to salt stripped centrosomes by soluble embryo extracts is prevented by immunodepletion of Asp. A: Nucleation of rhodamine labelled microtubules from partially purified centrosomes. The inset shows a single centrosome at higher magnification. B: Same field as A immunostained to reveal γ -tubulin. Routinely, 80% of γ -tubulin staining bodies were seen to nucleate asters of microtubules. C: Microtubule nucleation after extraction of the centrosomes with 1 M KI. D: Potassium Iodide-extracted centrosomes incubated with soluble extract from wild-type *Drosophila* embryos before the microtubule nucleation assay. E: Same field as D immunostained to reveal γ -tubulin. F: Same field as D, but using an extract immunodepleted of Asp. Scale bars, 10 μ m. G: Immunoblot of soluble embryo extract before (lane 1) and after immunodepletion of Asp (lane 2). The blot was probed with antibodies to Asp, CP190, KLP61F, polo and γ -tubulin as indicated.

Figure 4 A soluble extract from *asp*-derived embryos failed to restore MTOC activity to salt stripped centrosomes, but this ability can be rescued by purified Asp protein. A and C show the nucleation of rhodamine-labelled microtubules by KI-extracted centrosomes incubated with a soluble extract from a 3-hour collection of *asp^{ddl}*-derived embryos in the absence (A) or presence (C) of purified Asp protein (estimated concentration of 5×10^{-4} pmol/ μ l). The inset in C shows an MTOC at higher magnification. B is the same field as pannel C immunostained to reveal γ -tubulin. In this experiment, 70% of γ -tubulin staining bodies were seen to nucleate asters of microtubules. Scale bars, 10 μ m. D and E: Purification of Asp. D, silver stained SDS-PAGE gel and E, the corresponding Immunoblot probed with antibodies to Asp and β -tubulin. Lane 1, total extract; lanes 2-4, soluble fractions following sequential washes of GTP-taxol pelleted mictotubules with 500 mM NaCl, 750 mM NaCl and 1M KI.

EXAMPLES

Materials and Methods

Immunostaining of *Drosophila* brains was carried out as previously described (Gonzalez *et al.*, 1990). DNA was stained with TOTO3 (Molecular Probes) according to the suppliers instructions. Mitotic spindles were visualized by incubation with anti- α -tubulin monoclonal antibody (clone YL1/2 from Harlan Sera Labs) diluted 1:10. We detected γ -tubulin, using the monoclonal antibody from clone GTU88 (Sigma) at a 1:10 dilution. Anti-Asp was policlonal rabbit serum Rb3133 (Saunders *et al.*, 1997) diluted 1:50. Secondary antibodies were purchased from Jackson Immunochemicals and used according to the suppliers instructions. Preparations were visualised in a BioRad 1024 confocal scanning head in conjunction with a Nikon Optiphot microscope.

Centrosomes were purified from *Drosophila* embryos according to published protocols for the preparation of centrosomes from chinese hamster ovary cells (Barton *et al.*, 1995) The final centrifugation was through a 20-62.5% (w/w) sucrose gradient over a 70% sucrose

cushion in a SW27 (Beckman) rotor for 90 min at 65,000 g at 4°C.

Microtubule nucleation assays, extraction with 1 M KI and complementation assays were carried out as previously described (Moritz *et al.*, 1998). Microtubules were polymerised from *Drosophila* embryo extracts by addition of guanosine triphosphate (GTP) and taxol (Saunders *et al.*, 1997). The microtubule pellet was sequentially extracted with 500 mM NaCl, 750 mM NaCl and 1 M KI. Soluble fractions were concentrated by ultrafiltration using Millipore Ultrafree systems. Tubulin and rhodamin-labelled tubulin used in the centrosome nucleation assays were purchased from Molecular Probes.

Asp was immunodepleted from 100 µl of *Drosophila* embryo extracts by incubation with affinity-purified anti-Asp (20-50 µg) coupled to proteinG-Sepharose beads (Sigma).

SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels were blotted to polyvinylidene difluoride membranes (Millipore). The following antibodies were used: anti-Asp, Rb3133 (Saunders *et al.*, 1997); anti-KLP61F (Barton *et al.*, 1995); anti-Polo, MA294; anti-γ-tubulin GTU88 (Sigma); anti-β-tubulin, BX69. All primary antibodies were diluted 1:500, with the exception of MA294 and BX69 which were diluted 1:4. Peroxidase-conjugated secondary antibodies were purchased from Jackson Immunochemicals and used according to the suppliers instructions. Bound antibodies were detected by chemi-luminescence using chemicals from Amersham (ECL) or Pierce (Supersignal).

Results

Asp is a 220 kDa microtubule-associated protein (MAP) found at the poles of mitotic spindles in the syncytial embryos of *Drosophila melanogaster*. It has consensus phosphorylation sites for p34^{cdc2} and mitogen-activated protein kinases, and putative binding domains for actin and calmodulin. Mutations in *asp* result in abnormal spindle morphology leading to mitotic arrest, or to a high frequency of meiotic non-disjunction. Because the mitotic defects of *asp* mutants are best studied in the larval central nervous system, we sought to examine its distribution more carefully in cells of whole-mount

preparations of this tissue. We found that Asp became and remained associated with the centrosome throughout mitosis (Fig.1, A through C). At telophase, it migrated to microtubules on the spindle side of both daughter nucleus and was not associated with the centrosome in interphase cells. The immunolocalisation of Asp on the telophase spindle in cells of the larval brain is not shown. Asp is found in the region between the nuclei and the central spindle. At all mitotic stages from prophase to anaphase, the Asp protein was asymmetrically localised around the γ -tubulin in the PCM, where it appeared to form a hemi-spherical cup contacting the spindle microtubules (Fig. 1B).

In several *asp* mutations, Asp did not immunostain at the spindle poles. The mutant alleles that we examined are *asp^l*, *asp^{ddl}*, *asp^{dd4}*, *asp^{ddl}* and *asp^{dd8}* (White-Cooper *et al.*, 1996). The majority of mitotically arrested *asp* cells had bipolar spindles with broad unfocused poles of microtubules (Fig. 2, A and B). In a small proportion of cells, one pole could be sufficiently disorganised so that the spindle appeared monopolar. The γ -tubulin was not present within a well-organized centrosome in these cells but was found in dispersed clumps at the spindle poles (Fig. 2, C and D). This suggested that Asp might be required to maintain the structure of the centrosomal microtubule-organizing center (MTOC) during mitosis.

To confirm that Asp was a centrosomal protein, centrosomes were partially purified from syncytial *Drosophila* embryos undergoing their rapid nuclear division cycles). Immunoblotting experiments indicated that this preparation was enriched in both Asp and γ -tubulin (Fig. 1G). Moreover, these two proteins colocalized by immunofluorescence at *in vitro* organising centres for rhodamine-labeled microtubules (Fig. 1, D through F). In contrast to our observations *in vivo*, Asp was found in all of the *in vitro* MTOCs and was distributed symmetrically. First, this suggests that the extract was in a mitotic-like state, probably due to the dominant effect of the active mitotic protein kinase p34^{cdc2}. Second, it implies that the asymmetric localisation seen in intact cells requires that microtubules make contact with chromosomes to form a spindle. If Asp localises to the "outside" of the centrosome, we wondered whether antibodies to Asp might interfere sterically with microtubule nucleation in the *in vitro* assay. The centrosome preparation was therefore incubated with either affinity-purified anti-Asp or control rabbit immunoglobulins before

addition of rhodamine-labeled tubulin. A number of control antibodies have been used, including one against the centrosomal component CP190. None of these would prevent microtubule nucleation by the centrosome preparation. The number of asters of microtubules formed decreased in proportion to the concentration of antibody (Fig. 1H). However, the number of γ -tubulin positive bodies remained constant, suggesting that the antibody was blocking microtubule nucleation rather than disrupting the centrosomes.

Extraction of centrosomes with KI effectively destroyed their microtubule-nucleating activity leaving a centrosomal scaffold (Fig. 3C) (Schnakenberg *et al.*, 1998; Moritz *et al.*, 1998). Ability to nucleate microtubules can be restored to such KI-extracted centrosomes by incubation with the soluble fraction of a *Drosophila* embryonic extract (Fig. 3, D and E) (Moritz *et al.*, 1998). Although γ -tubulin and its ring-complex (γ TuRC) are required to rescue the aster-forming ability of KI-extracted centrosomes, they are not sufficient and have to be supplemented by a high molecular weight microtubule-associated factor postulated to be perientric (Moritz *et al.*, 1998). To test whether Asp protein might be required to reconstitute MTOCs from KI-extracted centrosomes, we immunodepleted Asp from a soluble embryonic extract under conditions where several other centrosomally associated proteins, including γ -tubulin, CP190, KLP61F and Polo, were not removed (Fig. 3G). This immunodepleted extract was unable to restore the ability of KI-extracted centrosomes to nucleate microtubules into asters. However, many linear arrays of microtubules were seen (Fig. 3F), suggesting that the Asp-depleted extract provided microtubule nucleation ability, but that it was not organised into discrete centres.

In contrast to the soluble extract of wild-type embryos, the equivalent soluble fraction prepared from *asp*-derived embryos was unable to restore the ability of KI-extracted centrosomes to nucleate asters of microtubules (Fig. 4A). We then investigated whether addition of purified Asp protein could restore this ability to the mutant embryo extract. Asp co-purifies with microtubules from *Drosophila* embryos but is not released by concentrations of NaCl known to remove most MAPs (Saunders *et al.*, 1997). Thus, it seemed that if KI extracts Asp from the centrosomes, it probably would do so from such purified microtubules. We extracted NaCl-washed microtubule preparations with 2 M KI, and a 220 kDa protein recognised by antibodies to Asp was found to be the main

component of the resulting supernatant fraction (Fig. 4 D and E). This purified Asp fraction was added to the soluble extract prepared from *asp*-derived embryos and found to restore the ability of KI-extracted centrosomes to nucleate asters of microtubules (Fig. 4, B and C).

Thus, it appears that both Asp and γ TuRC are required to restore microtubule nucleating activity to centrosome scaffolds. Because Asp neither co-purifies with the γ TuRC nor co-immunoprecipitates with γ -tubulin, it is unlikely to have a direct role in the nucleation process. Rather, the consequences of loss of Asp function upon spindle poles *in vivo* and upon MTOCs *in vitro* suggest that it is required to organise the γ TuRC within the PCM to form a nucleating centre for microtubules at mitosis. In *asp* mutants, a spindle can still form, most likely reflecting the known ability of mitotic chromatin and motor proteins to organize a bipolar spindle in the absence of centrosomes. However, one consequence of the disorganized centrosomes and spindle poles is that the cells arrest in a metaphase-like state, suggesting that the spindle integrity checkpoint has been activated. Asp protein function is likely to be modified later in the mitotic cycle, since it was observed to associate with the microtubules of the telophase spindle, a property consistent with its purification as a MAP. However, the lack of any obvious association with microtubules during interphase suggests that its properties have to be modulated, possibly by phosphorylation, during entry into mitosis in order to activate its essential role in maintaining the coherence of the centrosome at the spindle poles.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

References

- C. Gonzalez, R. D. Saunders, J. Casal, I. Molina, M. Carmena, P. Ripoll and D. M. Glover, *J. Cell Sci.* **96**, 605 (1990).
- J. Casal, C. Gonzalez, F. Wandosell, J. Avila and P. Ripoll, *Development* **108**, 251 (1990).
- B. J. Schnackenberg, A. Khodjakov, C. L. Rieder and R. E. Palazzo, *Proc. Natl. Acad. Sci. USA* **95**, 9295 (1998).
- M. Moritz, Y. Zheng, B. Alberts and K. Oegema, *J. Cell Biol.* **142**, 775 (1998).
- H. White-Cooper, M. Carmena, C. Gonzalez and D. M. Glover, *Genetics* **144**, 1097 (1996).
-
- N. R. Barton, A. J. Pereira and L. S. Goldstein, *Mol. Biol. Cell* **6**, 1563 (1995).
- A. A. Tavares, D. M. Glover and C. E. Sunkel, *EMBO J.* **15**, 4873 (1996).
- Lupas et al., *Science* **252**, 1162-1164 (1991).
- Cheney and Mooseker, *Current Opinion in Cell Biology* **41**, 27-35 (1992).

SEQUENCE LISTING

SEQ I.D. No. 1 - *Drosophila* Asp amino acid sequence (Genbank Accession No. U95171).

```

1    MELVWSPVLE VACKETLQLI DNRNFRKEVM IILKSKSNQP VKNPRKFPTV GKTLQLKSPT
61   GAGKTMKSVV SAAVQQKKRM SAAAAPPSKQ TWRVTAPSRP AAWAHPPPQA PLVEKNVYKT
121  PQEEPVIISP QPRSLKENLS PMTPGNLLDV IDNLRFTPLT ETRGKGQATI FPDNLAAWPT
181  PTLKGNVKSC ANDMRPRRIT PDDLEDQPAT NKTFDVKHSE TINISLDTLD CSRIDGQPHT
241  PLNKTITIVH ATHTRALACI HEEEGSPPPR TPTKSAIHDL KRDIKLVGSP LRKYESMKD
301  LSLSPQTKY AIQGSMPNLN EMKIRSIEQN RYYQEQIQI KAKDLNSSSS SEASLAGQQE
361  FLFNHSEILA QSSRFNLHEV GRKSVKGSVP KNPHKRRSHE LSFSDAPSNE SLYRNETVAI
421  SPPKKQRVED TTLPRSAAPA NASARSSSAH AWPHAQSKKF KLAQTMSLMK KPATPRKVRD
481  TSIQPSVKLY DSELYMQTCI NPDPFAATTT IDPFLASTMY LDEQAVDRHQ ADFKKWLNAL
541  VSIPADLDAD LNNKIDVGKL FNEVRNKELV VAPTKEEQSM NYLTKYRLET LRKAAVELFF
601  SEQMRLPCSK VAVYVKNQAL RIRSDRNHL DVVMQRTILE LLLCFNPLWL RLGLEVVFGE
661  KIQMQSNRDI VGLSTFILNR LFRNKCEEQR YSKAYLTEE YAETIKKHSL QKILFLLPFL
721  DQAKQKRIVK HNPCLFVKKS PHKETKDILL RFSSELLANI GDITRELRLR GYVLQHRQTF
781  LDEFDYAFNN LAVDLRDGVR LTRVVEVILL RDDLTRQLRV PAISRLQRIF NVKLALGALG
841  EANFQLGGDI AAQDIVDGHR EKTLSLLWQL IYKFRSPKFH AAATVLQKWW RRHWLHVVIQ
901  RRIRHKELMR RHRAATVIOA VFRGHQMRKY VKLFTERTQ AAIIQKFTR RYLAQKQLYQ
961  SYHSIITIQR WWRRAQQLGRQ HRQRFVELRE AAIFLQRIWR RRLFAKKLLA AAETARLORS
1021 QKQAAAASYI QMQWRTYQLG RIQRHEFLRQ RDLIMFVQRR MRSKWSMLEQ RKEFQQLKRA
1081 AINIQRWRA KLSMRKCNAD YLALRSSVLK VQAYRKATIQ MRIDRNHYYS LRKNVICLOQ
1141 RLRAIMKMRE QRENYLRLRN ASILVQKRYR MRQMIQDRN AYLRTKCI I NVQRRWRATL
1201 QMRREKKNYL HLQTTTKRIQ IKFRAKREMK KQRAEFLQK KVTLLVQKRR RALLQMRKER
1261 QEYLHLREVT IKLQRRFHAQ KSMRFMRKY RGTQAAVSCL QMHWNRHLLR KRERNSFLQL
1321 RQAAITLQRR YRARLNMIIQ LKSYAQLKQA AITIQTRYRA KKAMQKQVVL YQKQREAIK
1381 VQRRYRGNLE MRKQIEVYQK QRQAVIRLQK WWSIRDMLR CKAGYRRIRL SLSIQRKWR
1441 ATVQARRQRE IFLSTIRKVR LMQAFIRATL LMRQQRREFE MKRRAAVVIO RRFRARCAML
1501 KARQDYQLIQ SSVILVQRKF RANRSMKQAR QEFVQLRTIA VHLQQKFRGK RLMIEQRNCF
1561 QLLRCSMPGF QARARGFMAR KRFOALMTPE MMDLIRQKRA AKVIQRYWRG YLIRRRQKHQ
1621 GLLDIRKRIA QLRQEAKAVN SVRCKVQEAV RFLRGRFIAS DALAVLSQLD RLSRTVPHLL
1681 MWCSEFMSTF CYGIMAQAIR SEVDKQLIER CSRIILNLAR YNSTTVNTFQ EGGLVTIAQM
1741 LLRWCDKDSE IFNTLCTLIW VFAHCPKKRK IIHDYMTNPE AIYMVRETKK LVARKEKMKQ
1801 NARKPPPTS GRYKSQKINF TPCSLPSLEP DFGIIRYSPY TFISSVYAFD TILCKLQIDM
1861 F

```

SEQ I.D. No. 2 - *Drosophila* Asp nucleotide sequence (Genbank Accession No. U95171).

```

1    atggagctag tgtggagccc cgtccttgag gtggcctgca aggagacgct gcagctaata
61   gacaaccgca acttccgaaa ggaggtgatg atcatactca agtccaagag caaccagccg
121  gtcaagaacc cgcgcaaatt tcctactgtc ggcaagaccc tgcagctgaa atcgccgaca
181  ggagctggca agacaatgaa aagcgtggta tccgctgctg tgcagcaaaa gaagcgcgatg
241  tctgcagcag cagcgcctcc ctccaagcag acatggcgag tgactgctcc ttcgcgtccc

```

301 gctgcatggg cacatccacc tccacaggct cctcttgtcg agaagaatgt atacaagact
 361 ccacaagaag agcccgtata catatcacca cagcctcgca gtcttaagga aaatctaagc
 421 cctatgacgc caggaaacct actcgacgtg attgacaatc tgcgattcac acctctcacc
 481 gaaacccgtg gcaaaggaca agctaccatt ttcccggaca atctggcagc ctggcccaca
 541 ccaacactta aagggaatgt aaaatcatgt gctaatagata tgcggccgcg tcgaatcact
 601 ccagatgata tagaagatca gcctgccaca aacaaaacgt tcgatgtaaa gcattccgag
 661 actatcaata tttcgttga cacttggac tgctccagga tcgatggaca accgcatacg
 721 cccctaaata agacaacaac cattgtgcat gccacgcaca ccagagctct ggcctgtatt
 781 catgaggagg agggaccaag tccacctagg acgcccacga agagcgccat acacgacctg
 841 aagagggaca ttaagttggt gggttcaccc ttacgaaagt attccgagtc catgaaagat
 901 ttgtcacttc tatcgccaca aactaagtat gccattcaag ggtctatgcc taatctaaat
 961 gaaatgaaaa tccgctcgat cgaacagaat agatattacc aggagcagca gatccagata
 1021 aaggccaaag acttgaatag ctctctagt agcgaggcta gtttgccgg ccagcaggag
 1081 tttctattca accacagtga gatcctcgct cagtccagtc gttttaatct ccatgaagta
 1141 ggtcggaaagt cgggtgaaggg aagtccggtg aagaatcctc acaagcgccg ctctcatgag
 1201 ttgagttttt cggatgcacc tagcaacgaa tcattgtacc gcaatgaaac tgtagccatt
 1261 tcccctccta aaaagcaacg ggttgaggac actactctgc ccagaagtgc agcgccggca
 1321 aatgcatctg caagaagcag tagtgccac gcctggccac acgcccacac caagaagttt
 1381 aagctagcac aaacctatgtc actgatgaag aagcccgcca caccacgaaa agtcagggac
 1441 actagcattc agccttccgt caagctctat gactcggagc tgtatatgca gacgtgcatc
 1501 aaccggatc catttgcagc aactacgaca attgatccat ttctggcatc taccatgtat
 1561 ttggatgaac aggtgtgga tcgtcatcaa gctgacttta aaaagtgggt aaatgccctt
 1621 gtctccatac ccgctgacct ggacgcagat ttaaataaca aaatagacgt tggtaaagctg
 1681 ttaacgagg tgcgcaacaa agagctcgtg gtggctcca ccaaggagga gcagtctatg
 1741 aactacctaa cgaaataccg cctggagacg ctctgtaagg cggctgtgga gctcttcttc
 1801 agtgagcaga tgcgcctgcc atgctccaaa gtggccgtat atgtcaacaa gcaagctctg
 1861 cgcacccgta gcgatcgtaa tcttcaccta gacgtagtta tgcaacgcac catacttgag
 1921 ctgctgcttt gcttcaatcc ctttggctg cgccttggac tggaagtgggt ctttggcgag
 1981 aagatccaga tgcagtctaa tcgagacatt gtaggcctca gcacctttat cctcaatcgc
 2041 ttgttccgga ataagtgtga ggagcagagg tacagcaagg catacacact caccgaagag
 2101 tacgcgga cattaagaa gcaactcatt cagaaaaatcc tctttttgct gcctttcctc
 2161 gatcaagcta agcagaagcg catcgtcaag cacaatccct gtttgtttgt taaaaagtcg
 2221 ccacataaag agaccaagga tattctgctg cgcttctcgt cggagctgct cgccaacatt
 2281 ggtgatatta cgcgggaact tcgtcgctg ggctacgttc tacagcaccg ccaaacattt
 2341 ttggacgagt tcgattatgc cttcaacaac ttggctgtgg acctaaagaga tggcgtgaga
 2401 ctaacccgag tcgtggaggt aattttacta cgcgatgatc taacccgcca gtttaagggtg
 2461 ccagccatct ctgccttca gcgatcttc aatgtaaagc tagctctggg cgcacttggt
 2521 gaagccaact tccagctagg cggcgacatc gccgccaag acatcgttga cggacatcgt
 2581 gagaagacgc tttccctgct ctggcaactt atttacaat tccgctcgcc caagtttcat
 2641 gcggcgcca cgggtgctcca gaaatggtgg cgccgtcact ggctgcacgt tgttatccag
 2701 cgtcgcattc gccacaaaga gcttatgctg cgccaccggg ccgctactgt cattcaggcc
 2761 gtgttccgtg gccaccagat gagaaagtac gtgaagttgt ttaagacgga acgcactcag
 2821 gccgcaataa ttctgcaaaa gttcacccgt cggtatttgg ccagaagca gctatatcag
 2881 agctatcaca gtattatcac catccagcgc tgggtggcgag cccaacaact gggaaggcag
 2941 caccgccagc ggtttgtgga gctccgagag gctgcgatct ttcttcagcg gatctggcgg
 3001 cgacgactct ttgccaaaaa actattggcg gcggcggaag cagccagact tcagcgatcg
 3061 caaaaacaac aggcagctgc tagttatatt caaatgcaat ggcaacgta tcagctgggc

3121	agaattcagc	gacacgagtt	cctgcgccag	agggacctca	tcatgtttgt	tcagcgcagg
3181	atgcgaagca	agtggagtat	gctggagcag	cgcaaggagt	tccagcaact	aaagcgtgca
3241	gctataaata	tccaacaacg	ctggcgagcg	aagctttcaa	tgagaaagtg	caacgctgat
3301	tatttggcac	ttcgttccag	cgttcttaaa	gttcaggctt	acaggaaagc	cacaatccag
3361	atgagaatag	atcgtaatca	ctactattcc	ctgcgaaaaa	atgttatctg	cctgcaacag
3421	cgactgaggg	ccatcatgaa	aatgcgcgaa	cagagggaaa	attatctgag	gctgcgaaat
3481	gcttcaatac	tagttcaaaa	acgctaccgc	atgcgtcaac	aatgatcca	ggatagaaat
3541	gcatatttaa	gaaccgcgaa	atgtatcatc	aatgtccaga	ggcgtgagg	agccactctg
3601	cagatgcgtc	gagaaaggaa	gaactacctt	catctccaaa	cgacaaccaa	acgaattcaa
3661	atcaagttcc	gtgccaaagc	cgaaatgaaa	aagcaaagag	ccgagtttct	tcagctgaaa
3721	aaggttacc	ttgtagtcca	gaaacgtcgg	cgggctttgc	tgcagatgcg	aaaggagcgc
3781	caggagtacc	tacatctgcg	cgaggttacc	ataaagctgc	agcgcagatt	ccatgctcaa
3841	aaatcaatgc	ggttcatgcg	agccaagtac	cgcggcacc	aggctgctgt	gagctgcctg
3901	cagatgcatt	ggcgtaatca	tctccttagg	aaacgggaga	ggaacagttt	cttacaactg
3961	cgtcaagcag	caataacact	gcagcgacgg	taccgagctc	gtctgaatat	gatcaagcag
4021	ttgaagagtt	acgcccagct	gaaacaggca	gctattacca	ttcaaaccg	atatagagcc
4081	aagaaggcaa	tgcaaaagca	ggtggtcttg	tacaaaagc	aaagggaagc	cattatcaaa
4141	gtgcaacgac	gataccgcgg	caatctggag	atgaggaagc	agattgaagt	ctacaaaaa
4201	cagcgccagg	cagtcatccg	cttgcaaaaa	tggtggcgca	gtatacgca	catgcggctg
4261	tgcaaaagcg	gctaccgaag	gattcgactc	agttcattga	gcattcaacg	caagtggcgg
4321	gccacagtgc	aggctcgtcg	ccaacgggag	atcttcttaa	gcaccatccg	caaagtgcga
4381	cttatgcagg	catttatcag	agcaacttta	ctgatgcgtc	agcagcgag	ggaattcgag
4441	atgaagcgaa	gggctgccgt	agtgatccag	cgccggtttc	gtgctcgctg	tgctatgcta
4501	aaggcgagac	aggattacca	attaatccaa	tcctctgtga	tcctggtgca	gcgcaaattc
4561	cgtgctaata	gcagcatgaa	gcaggcacgc	caggaatttg	tccagctgcg	tactattgca
4621	gtccatttgc	aacaaaagtt	ccgtggcaag	cgtctaata	ttgagcagcg	taattgtttc
4681	caactgctcc	gctgttccat	gccgggcttc	caggcacgtg	cccgcggctt	tatggctcgc
4741	aaacgattcc	aggccctgat	gacaccgag	atgatggacc	tcacccgca	gaagcgcgcc
4801	gccaaaggta	tacagcggtta	ctggcggggc	tatctaata	gacgacgtca	gaagcaccag
4861	ggtctcttgg	atatccggaa	gcgtattgct	cagctgcggc	aagaggcaaa	ggcggtaaac
4921	tctgtgcgct	gcaaagtcca	ggaggcggtg	cgtttccttc	gcggacgctt	tatcgcatca
4981	gatgcgttag	cagtgtctaa	tcaattggat	cgtctttcgc	gcactgtgcc	acacctgctc
5041	atgtggtgtt	cggagttcat	gtccacgttt	tgctatggca	tcattggtca	ggccattcga
5101	tcagaggtgg	ataagcagct	tatagagcgc	tgacgcccga	tcattcctaa	tttgcccgc
5161	tacaatagca	ccacggtgaa	cacgttccag	gagggcggtt	tggtcaccat	tgcccagatg
5221	ttattgcgct	ggtgcgacaa	agacagttag	atattcaaca	ctttgtgcac	cctcatttgg
5281	gtattcgccc	actgtcctaa	aaagcgaaa	atcattcacg	actatatgac	caaccagag
5341	gccatttaca	tggtgcgcga	aactaagaag	ctcgtggccc	gcaaggaaaa	gatgaagcaa
5401	aatgcacgca	agccgcgcgc	aatgacaagt	ggacggtata	agagccaaaa	gataaacttc
5461	acgccgtgtt	ccctgcccag	cctggagccg	gacttcggaa	tcacccgcta	cagtccttac
5521	acgtttatct	cgtccgttta	cgccttcgat	acgattttgt	gcaagctgca	gatcgacatg
5581	ttttag					

1. A method for identifying a substance capable of disrupting microtubule organising centre (MTOC) integrity, which method comprises
contacting an Asp polypeptide or homologue thereof, or fragment thereof capable of forming and/or maintaining MTOCs in the absence of the substance, with a candidate substance in the presence of components required for MTOC formation and microtubule nucleation therefrom, and determining whether the substance disrupts MTOC integrity.
2. A method according to claim 1 wherein said components comprise KI-extracted centrosomes and an Asp-depleted soluble cellular extract.
3. A method according to claim 1 wherein said components comprise a partially purified centrosome preparation and tubulin.
4. A method according to any one of claims 1 to 3 wherein said Asp polypeptide is as shown in SEQ I.D. No. 1 or a fragment or derivative thereof capable of stimulating the formation of and/or maintaining MTOCs.
5. A method according to any one of claims 1 to 3 wherein said Asp polypeptide is a mammalian homologue of the polypeptide shown in SEQ I.D. No. 1, or a fragment or derivative thereof capable of stimulating the formation of and/or maintaining MTOCs
6. A method according to any one of claims 1 to 5 further comprising administering a said substance, which has been determined to disrupt MTOC integrity, to a cell and determining whether the substance inhibits mitosis in the cell.
7. A substance identified by the method of any one of claims 1 to 6.
8. A substance capable of disrupting MTOC integrity which substance is selected from peptides consisting essentially of from 5 to 35 amino acids comprising a amino acid sequence selected from residues x-y of SEQ I.D. No. 1 wherein x-y is 267-271, 272-276,

291-295, 387-391, 421-425, 473-477, 140-144, 237-241, 269-273, 471-475, 155-160, 237-243, 743-875, 911-940, 1293-1322, 1374-1403, 1563-1591 and 1597-1624.

9. A substance capable of binding to an Asp polypeptide or homologue or fragment thereof for use in a method of disrupting MTOC integrity.

10. A substance according to claim 9 which is an antibody.

11. A polypeptide fragment of an Asp polypeptide or homologue thereof, which fragment is not capable of restoring microtubule nucleation centre organising activity to an Asp-depleted extract, for use in a method of disrupting MTOC integrity.

12. A polypeptide fragment according to claim 11 selected from peptides consisting essentially of from 5 to 35 amino acids comprising a amino acid sequence selected from residues x-y of SEQ I.D. No. 1 wherein x-y is 267-271, 272-276, 291-295, 387-391, 421-425, 473-477, 140-144, 237-241, 269-273, 471-475, 155-160, 237-243, 743-875, 911-940, 1293-1322, 1374-1403, 1563-1591 and 1597-1624.

13. A polynucleotide encoding a polypeptide according to claim 10 or 11 for use in disrupting MTOC integrity.

14. A nucleic acid vector comprising a polynucleotide according to claim 12.

15. Use of an Asp polypeptide or homologue thereof, or fragment thereof capable of stimulating formation of and/or maintaining MTOCs, in an assay for identifying a substance capable of disrupting MTOC integrity.

16. A substance according to claim 8, 9 or 10 for use in a method of disrupting MTOC integrity.

17. A process comprising the steps of:

(a) performing the method according to any one of claims 1 to 6; and

(b) preparing a quantity of those one or more substances identified as being capable of disrupting MTOC integrity.

18. A process comprising the steps of:


- (a) performing the method according to any one of claims 1 to 6; and
 - (b) preparing a pharmaceutical composition comprising one or more substances identified as being capable of disrupting MTOC integrity.
-

ABSTRACT

A method is provided for identifying a substance capable of disrupting microtubule organising centre (MTOC) integrity, which method comprises

contacting an Asp polypeptide or homologue thereof, or fragment thereof capable of forming and/or maintaining MTOCs in the absence of the substance, with a candidate substance in the presence of components required for MTOC formation and microtubule nucleation therefrom, and determining whether the substance disrupts MTOC integrity.

THIS PAGE BLANK (USPTO)



G

1 2 3 4 5 6

— ← Asp

- - - ← γ -tubulin




Figure 1

THIS PAGE BLANK (USPTO)




Figure 2

THIS PAGE BLANK (USPTO)




Figure 3

THIS PAGE BLANK (USPTO)




Figure 4

PCT NO : GBT / 00785

Form 23/77 : 3 3 00

Agent : D Young & co

THIS PAGE BLANK (USPTO)